Healthcare Industry News: Mylan
News Release - September 14, 2007
Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance OfficerPITTSBURGH, Sept. 14 (HSMN NewsFeed) -- Mylan Laboratories Inc. (NYSE: MYL ) today announced the appointment of M. Fabiana Lacerca to the position of Senior Vice President and Chief Compliance Officer.
Ms. Lacerca joins Mylan from Bristol-Meyers Squibb where she was Director of Compliance for Latin America, Canada and Puerto Rico. While there, she was responsible for all compliance-related matters in those regions. Prior to Bristol-Meyers Squibb, Ms. Lacerca held executive and senior counsel positions with Merck & Co., Microsoft and AT&T.
Ms. Lacerca has extensive experience in the areas of multi-jurisdictional corporate compliance, international business transactions, pharmaceutical industry regulation, corporate policy and international environmental law and has advised on opportunities and legal trends within the government as well as corporate sectors.
Mylan Vice Chairman and CEO Robert J. Coury commented: "As we transition to becoming a global leader in our industry we are committed to maintaining a culture of integrity and quality across all lines of our business. It is with great pleasure, therefore, to welcome Fabiana to Mylan. Fabiana has tremendous experience and an exemplary track record in international corporate compliance, which she has gained advising a number of Fortune 100 companies on a wide range of issues, including corporate policy and cross border transactions. Fabiana's extensive experience counseling companies in the pharmaceutical industry with operations in multiple countries will be invaluable to Mylan's operations around the world."
Ms. Lacerca earned a master's of law (LL.M) from UCLA; a specialization in international environmental law from the Universidad de Buenos Aires; and a bachelor's of law from the Universidad de Buenos Aires.
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products. For more information about Mylan, please visit www.Mylan.com.
Source: Mylan Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.